Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Tofacitinib Uptake By Patient-derived Intestinal Organoids Predicts Individual Clinical Responsiveness.

Tofacitinib uptake by patient-derived intestinal organoids predicts individual clinical responsiveness.

Kyung Ku Jang, Defne Ercelen, Jing Yu Carolina Cen Feng

    Biorxiv : the Preprint Server for Biology
    |May 7, 2024

    Related Experiment Videos

    Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
    12:41

    Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

    Published on: December 23, 2022

    4.8K
    Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
    08:52

    Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

    Published on: November 22, 2021

    4.0K
    Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
    07:04

    Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

    Published on: February 11, 2017

    19.2K

    View abstract on PubMed

    Summary
    This summary is machine-generated.

    Patient-derived organoids can predict how well ulcerative colitis patients respond to tofacitinib treatment. This approach identifies reduced MATE1 transporter levels as a key factor in non-response to this Janus kinase (JAK) inhibitor.

    Area of Science:

    • Gastroenterology
    • Pharmacogenomics
    • Translational Medicine

    Background:

    • Achieving remission in ulcerative colitis (UC) is challenging, with frequent nonresponse to therapies.
    • Current treatment selection lacks guidance for individualizing therapy.
    • Predicting response to Janus kinase (JAK) inhibitors like tofacitinib is crucial.

    Conclusions:

    • Patient-derived intestinal organoids effectively predict individual tofacitinib responsiveness in UC.
    • MATE1 transporter expression is a key predictor of clinical response to tofacitinib.

    Related Experiment Videos

    Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
    12:41

    Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

    Published on: December 23, 2022

    4.8K
    Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
    08:52

    Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

    Published on: November 22, 2021

    4.0K
    Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
    07:04

    Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

    Published on: February 11, 2017

    19.2K